U.S. Markets closed

Heat Biologics, Inc. (HTBX)


NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.7014-0.02 (-2.45%)
At close: 4:00PM EDT
People also watch
NVCNEVOKEBIOIMNPSKLN
Interactive chart
Previous Close0.7190
Open0.7070
Bid0.5500 x 300
Ask0.7200 x 500
Day's Range0.7014 - 0.7500
52 Week Range0.5200 - 3.3500
Volume433,575
Avg. Volume773,426
Market Cap24.98M
Beta1.28
PE Ratio (TTM)-0.98
EPS (TTM)-0.71
Earnings DateAug 14, 2017 - Aug 18, 2017
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.00
Trade prices are not sourced from all markets
  • American City Business Journals16 days ago

    Heat Bio pivots, will focus on combination therapies for cancer

    Along with its first quarter results, Durham’s Heat Biologics (HTBX) has outlined a new strategy focusing on combination therapies for the treatment of cancer – specifically, with checkpoint inhibitors or T cell co-stimulators – alone. The strategy comes at a time when the company has seen positive data from its ongoing Phase 2 trial of HS-110 for the treatment of lung cancer in combination with Bristol-Myers Squibb checkpoint inhibitor nivolumab,according to Heat CEO Jeff Wolf said Thursday. Heat Biologics plans to discontinue its other clinical program for the treatment of non-muscle invasive bladder cancer, along with additional preclinical programs, in order to focus those resources on combination programs, he says.

  • Accesswire16 days ago

    Heat Biologics Provides Business and Clinical Update for the First Quarter of 2017

    Heat to Double-Down on Checkpoint Combination Therapies Based on Positive Interim Data of HS-110+PD-1 Checkpoint in Lung Cancer; Acquires Pelican Therapeutics Which Brings with it a $15.2 Million CPRIT ...

  • American City Business Journals25 days ago

    Heat Bio completes acquisition of Texas company

    Durham’s Heat Biologics (HTBX) has completed its acquisition of Austin, Texas-based immuno-oncology company Pelican Therapeutics, in a cash-and-stock deal valued at about $1.5 million . "We’ve been following Pelican and thinking about [the acquisition] for quite a while," said Heat CEO Jeff Wolf in an interview at the time of the deal’s announcement in March. "Pelican's two product candidates strengthen our portfolio in the emerging T cell activation space,” said Wolf in a statement, regarding the deal’s closing.